Side-by-side · Research reference

TesamorelinvsVesugen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedFlagship27/68 cited

BAnimal-MechanisticHUMAN-REVIEWED5/43 cited

Tesamorelin

GHRH Analogue · FDA-Approved

2 mgDaily doseEGRIFTA® (tesamorelin for inje 2010

15–20%VAT reductionFalutz 2010

~26 minHalf-lifeEGRIFTA® (tesamorelin for inje 2010

SQ · Abdomen · Once Daily

Vesugen

Bioregulatory Tripeptide · Vascular Endothelium

3 AATripeptide

Endothelin-1 ↓Atherosclerotic tissue

Ki-67 ↑Aged endothelium

SQ / IM · Protocol varies

01Mechanism of Action

Parameter

Tesamorelin

Vesugen

Primary target

Hypothalamic GHRH receptorsEGRIFTA® (tesamorelin for inje 2010

Vascular endothelial cell nucleus — MKI67 gene promoter

Pathway

GHRH → Pituitary GH release → Liver IGF-1 synthesisFalutz 2007

KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑

Downstream effect

Increased GH pulsatility, elevated IGF-1, lipolysis of visceral adipose tissueFalutz 2010

Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016 Khavinson 2014

Feedback intact?

Yes — physiological pulsatility preserved

Not applicable — does not operate via hormone axis

Origin

Synthetic 44-AA GHRH analogue with trans-3-hexenoic-acid modification for stabilityEGRIFTA® (tesamorelin for inje 2010

Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator

Antibody development

~50% after 26 wks (non-neutralising in most)Sévigny 2018

—

02Dosage Protocols

Parameter

Tesamorelin

Vesugen

Standard dose

2 mg / dayEGRIFTA® (tesamorelin for inje 2010

FDA-approved protocol.

—

Frequency

Once daily (morning or pre-sleep)

Aligns with natural GH pulse.

Not specified in available literature

Lower / starter dose

1 mg / dayFalutz 2010

1 mg still produces significant IGF-1 elevation.

—

Evidence basis

RCT / FDA-approvedFalutz 2007 Falutz 2010

Animal models (atherosclerosis, restenosis, aging) · Russian case series

Duration

12–52 weeks

VAT returns within months of stopping.

Case series report treatment courses in elderly arterial insufficiency

Reconstitution

Sterile water per labeling

Preserved at 2–8 °C after reconstitution.

—

Timing

Empty stomach, pre-sleep preferred

—

Half-life

~26 min (plasma)EGRIFTA® (tesamorelin for inje 2010

Modified vs native GHRH (7 min t½).

Not reported

Tripeptides typically cleared rapidly.

Standard dose (reported)

—

Not standardised — Russian clinical case series

Protocols vary; no FDA-approved regimen.

Route

—

Subcutaneous or intramuscular

03Metabolic / Fat Loss Evidence

Parameter

Tesamorelin

Vesugen

Primary fat target

Visceral adipose tissue (VAT) — abdominal

—

Quantified reduction

15–20% VAT ↓Falutz 2010

By CT at 26 weeks (Falutz et al., NEJM).

—

IGF-1 impact

+66 ng/mL (2 mg dose) · +81% mean elevationFalutz 2007

—

Effect on lean mass

Modest lean mass preservation / slight increase

—

Insulin sensitivity

Neutral to slight impairment (monitor HbA1c)Clarke 2018

—

Triglycerides

Significant TG reduction noted in Phase 3Falutz 2010

—

Glucose metabolism

Generally neutral; 4.5% HbA1c elevation riskClarke 2018

—

Effect reversibility

VAT returns within months of stopping

—

Key publication

Falutz et al. NEJM 2007 · Falutz JCEM 2010 · FDA approval 2010Falutz 2007 Falutz 2010 EGRIFTA® (tesamorelin for inje 2010

—

04Side Effects & Safety

Parameter

Tesamorelin

Vesugen

Injection site reaction

Erythema, pruritus, redness (common)

—

Fluid retention / Edema

Peripheral edema, arthralgia, carpal tunnel (GH-axis effect)

—

Glucose intolerance

HbA1c ↑ in 4.5% vs 1.3% placebo; HbA1c ≥6.5% hazard OR 3.3Clarke 2018

—

IGF-1 elevation

Dose-dependent; supraphysiological levels = discontinue

—

Cancer risk

Contraindicated in active malignancy (GH/IGF-1 axis); theoretical tumour growth riskEGRIFTA® (tesamorelin for inje 2010

—

Antibody formation

~50% at 26 weeks; non-neutralising in most; rare hypersensitivity (<1%)Sévigny 2018

—

GI symptoms

Nausea, diarrhea (mild, transient)

—

Pregnancy / OB

ContraindicatedEGRIFTA® (tesamorelin for inje 2010

—

Reported adverse events

—

None documented in available abstracts

Injection site

—

Assumed minimal — typical for small peptides

Long-term safety

—

Unknown — no long-term RCT data

Epigenetic mechanism risk

—

Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised

Absolute Contraindications

Tesamorelin

·Active malignancy or history of treated cancer
·Pregnancy
·Hypersensitivity to tesamorelin or mannitol
·Disruption of hypothalamic-pituitary axis (trauma, tumour, radiation)

Vesugen

—

Relative Contraindications

Tesamorelin

·Untreated diabetes (monitor HbA1c)
·Severe carpal tunnel syndrome
·Acute critical illness

Vesugen

·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context

05Administration Protocol

Parameter

Tesamorelin

Vesugen

1. Reconstitution

Add 2.1 mL sterile water to 2 mg lyophilised vial. Roll gently — do not shake. Solution should be clear.

Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.

2. Injection site

Subcutaneous — abdomen preferred. Rotate sites (avoid same spot within 2 cm). Avoid navel and waistband area.

Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.

3. Timing

Once daily. Preferred: evening, 2–3 hrs post-meal, before sleep — aligns with natural GH secretion pulse.

No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 21 days.

Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).

5. Needle

27–31G, 4–8 mm insulin syringe. Pinch skin, 45° angle for lean individuals.

—

06Stack Synergy

Tesamorelin

+ Ipamorelin

Strong

View Ipamorelin →

Tesamorelin (GHRH analogue) and ipamorelin (GHRP / ghrelin mimetic) act on two distinct receptor systems to amplify GH release synergistically — GHRH receptor + ghrelin receptor. This dual-axis stimulation produces a more robust, sustained GH pulse than either alone while maintaining physiological pulsatility. Ipamorelin is highly selective with minimal cortisol or prolactin elevation, making it the preferred GHRP pairing.

Tesamorelin: 2 mg SQ · evening
Ipamorelin: 200–300 mcg SQ · same injection
Frequency: Once daily, pre-sleep
Primary benefit: Maximal GH pulsatility, fat loss, recovery, sleep quality

Raun 1998

Vesugen

+ Thymalin

Multi-pathway

View Thymalin →

Both from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.

Vesugen: Per protocol (SQ/IM)
Thymalin: Per protocol (SQ/IM)
Frequency: Sequential or concurrent per geroprotective protocol
Primary benefit: Multi-system age-related decline mitigation (vascular + immune)